Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3CNS 3Thoracic 2Plasma cell 1Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 34Pheochromocytoma 4Paraganglioma 4Carcinoma, Neuroendocrine 4Sarcoma 3Pancreatic Neoplasms 3Neoplasms 3Meningioma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Carcinoid Tumor 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Melanoma 2Medulloblastoma 2Liver Neoplasms 2Insulinoma 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Digestive System Neoplasms 2Colonic Neoplasms 2

Interventions

repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × NET × 30 days × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡